U.S. Point-of-Care Glucose Testing Market (2024 - 2030)

Market Size & Trends

The U.S. point-of-care glucose testing market size was valued at USD 1.15 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 4.5% from 2024 to 2030. The rapid surge in geriatric population, improved accuracy of these point of care devices, and rapid advancements in mobile glucose monitoring apps are significantly driving the market growth.

In 2023, U.S. accounted for a market share of over 34% in the global point-of-care glucose testing market. Large population at high risk of diabetes in the U.S. is a key factor contributing to growth in product demand. As per the CDC, diabetes is the 7th most common cause of death in the U.S. with over 38.4 million (i.e. 11.6% of the population) Americans had diabetes in 2021,. The presence of government organizations focusing on creating awareness regarding diabetes and glucose testing products available in the market has propelled the growth in the country. For instance, the American Heart Association, American Diabetes Association, and Pan American Health Organization are especially involved in such initiatives.

Rising healthcare expenditure for diabetes and increasing cost per person on diabetes are boosting the demand. Manufacturers in the U.S. are creating advanced diabetes management platforms, which is boosting the demand for POC glucose diagnostic products. For instance, One Drop is a diabetes management company that integrates data science with mobile computing.

Market Characteristics & Concentration

The industry is expected to continue its growth trajectory for the coming 5-6 years as a huge percentage of the U.S. population is currently at danger of developing diabetes, which is a result of sedentary lifestyle, high blood pressure, obesity, smoking, and excessive alcohol consumption. This is projected to spur the demand for point-of-care glucose testing solutions.

Technological advancements such as the improvements in connectivity, design and accuracy aimed at improving functionality and efficacy are the key areas market players focusing on. The country is focusing on the digitalization of healthcare by leveraging innovative technologies, such as AI, big data, and cloud computing. Several players are launching various products to strengthen their product portfolio. This strategy enables companies to increase their customer reach, expand their product portfolios, and improve their offerings. For instance, in January 2022, Roche unveiled the launch of the Cobas pulse, a point-of-care blood glucose monitoring device designed for hospital personnel. The device comes with an add-on gadget developed like a touchscreen smartphone, which runs its own apps.

The U.S. point-of-care glucose testing industry is characterized by a high level of M&A and collaboration activities undertaken by leading players to increase their product portfolio and customer base. For instance, in June 2020, Tandem Diabetes Care and Abbott finalized an agreement to commercialize and develop an integrated diabetes solution that combines Tandem’s insulin delivery system and Abbott’s CGM technology.

The introduction of favorable regulatory policies aimed at promoting POC glucose diagnostics is expected to drive product demand. For instance, the implementation of Clinical Laboratory Improvement Amendments (CLIA) is expected to boost usage rates. CLIA-waived tests are approved for use by healthcare providers operating in nontraditional laboratory sites such as emergency rooms, physician offices, pharmacy clinics, health department clinics, and other healthcare facilities. CLIA-waived tests are associated with a smaller number of inaccurate results as they are simple laboratory examinations approved by the FDA for home use.

Product Insights

Accu-Chek Inform II accounted for the largest market share of 18.0% in 2023. This product is designed for in-vitro diagnostic procedures that help in monitoring blood glucose level. This glucose meter determines the level of blood glucose in venous, capillary, whole blood, and neonatal & arterial samples. Several healthcare professionals use Accu-Check Inform II, as it acts as a bedside monitoring solution aiding in determination of glucose and automates management of data generated by blood glucose tests. This helps healthcare professionals offer quality patient care.

Freestyle lite is expected to witness the fastest growth over the forecast period. FreeStyle Lite by Abbott is offered in discreet size with embedded backlight and port light, making it user-friendly for patients with a busy lifestyle. This device is used for determining blood glucose levels from blood samples collected from fingers, upper arm, forearm, hand, and thigh.

Key U.S. Point-of-Care Glucose Testing Company Insights

Some of the key U.S. point-of-care glucose testing players in are F. Hoffmann-La Roche Ltd., Abbott, LifeScan, Inc., and Bayer AG/Ascensia Diabetes Care Holdings AG among others. The industry is highly fragmented with the presence of many large, small, and medium-scale manufacturers. Key players are focusing on various business growth strategies, including new product launches, collaborations, expansion, partnerships, and acquisitions.

Recent Developments

• In January 2024, Roche announced the acquisition of LumiraDx’s point of care technology in a deal valuing over USD 350 million. This deal offered Roche a diverse range of clinical chemistry and immunoassay tests, having the potential for added high-medical value tests in the upcoming years.

• In February 2023, Insulet Corporation acquired the assets of Automated Glucose Control LLC (AGC). AGC specializes in automated insulin delivery technology. With the help of this transaction, Insulet planned to make prominent innovations in developing automated insulin delivery technology.

U.S. Point-of-Care Glucose Testing Market